Download pdf - Pdr Reference

8/14/2019 Pdr Reference

1/4

As an Immunotec entrepreneur,youre constantly responding to ques-tions about Immunocal. People natural-ly want to know more about the prod-uct, how it works, the science behindImmunocal, etc. Some of the most fre-quent questions that Immunotec entre-preneurs have to deal with relate to howImmunocal is different from otherwhey-based products. These questionsare usually asked in two instances:

When competitive products makesimilar claims

Whenever Immunocal is higher priced

So, how is Immunocal different

from other whey-based products?One typical response is to present a

long list of scientific data and graphsshowing comparative biological activityand immune response, etc. One of theproblems with this method is that num-bers can be easily manipulated to gen-erate a positive outcome. In reality,however, results in the real world are allthat matter. As John Molson, Vice-President of Research & Developmentat Immunotec says, "The only real wayto measure the bioactivity (effective-ness) of Immunocal, and any otherproduct for that matter, is in vivo (human) studies."

Our credentials setImmunotec ResearchLtd. apart. We deter-mine the industry stan-dard with our pharma-ceutical-grade productImmunocal. Our product

U.S. Edition2 5

The EntrepreneurI M M U N O T E C R E S E A R C H L T D . w w w . i m m u n o c a l . c o m

F a l l 9 9

RESEARCHbringing HEALTH and WEALTH

Dr. Roger Mazlen is a senior attending physician in endocrinology and metabolism at Mount Sinai hospital in New York City. He is a trained clinical pharmacologist and a member of the Am erican Society for Clinical Pharmacology and Therapeutics.He is the host of a radio program on WEVD in New York dedicated to discourse on the latest research in the medical field. In October, Dr. Mazlen will be a participant at "Summit 2000" - Immunotecs largest annual gathering.

Q: Dr. Mazlen, can you tell us whatareas you are concentrating on withyour new studies and what roleImmunocal plays in them?

A: I am currently involved in an ongoingstudy of prostate cancer utilizing andmeasuring the effects of Immunocal,and am also at the design stage ofresearch for a clinical study of patientssuffering from Chronic Fatigue Syn-drome. Actually, in the case of Chronic

Fatigue Syndrome, I have been involvedin research determining the viral agentsthat cause the disease for the last tenyears.

Q: So the research with patients suffer-ing from prostate cancer is in full swing?

A: Yes. The experiment has been on-going since last summer. We are usingImmunocal as an adjunctive treatmentwith those patients who are receivingtreatment but not responding to it, and

with patientswho are notcurrently re-ceiving treat-ment. Prostatecancer may beeither malig-nant or benign,so we are actu-ally testing Im-munocal ontwo groups:

those suffering from benign prostatichypertrophy where the biopsy has pro-ved negative, and on those actually suf-fering from prostate cancer. Patientsreceive Immunocal accompanied byImmunotecs Co-Factor Multi-VitaminSupplement that augments its effects.Treatment is open-ended so long as thepatient benefits.

Q: Have you been able to draw any defi-nite conclusions from your study of Im-munocal with prostate cancer patients?

A:While it is early yet for any final con-clusions, we are extremely encouragedby the preliminary findings and arelooking for ways of expanding ourstudy in the hopes of finding morenumerical data. We have had prelimi-nary success with prostate cancerpatients where test results reflected

Setting The StandardImmunocal vs. the Competition

Immunocal

Earns a Place InThe U.S. Physicians' Desk ReferenA Proud New Page in the History of Immunotec

The fact is that the research mostcompetitive whey products use as abasis for their claims was conducted byGustavo Bounous M.D. and his team inthe development of Immunocal. UnlikeImmunocal, these other products have

not withstood the test of real research.Whether they actually work is any-body's guess.

Immunotec Research Ltd. is a dedicated network marketing company, committed to the pursuit of financial freedom for our entrepreneurs by providing the highest quality health products backed by medical research and the credibility of the scientific community.(Immunotec's Mission Statement)

Medical research and the credibili-ty of the scientific community set

Please see Immunocal , page 3Please see Dr. Mazlen , page 4

Dr. Roger Mazlen

Please see Reference , page 3

The Doctor Is InIn Conversation with Dr. Mazlen

is patent-protected, backed by medicalresearch and eligible for reimbursementcoverage. And now it is with pride thatwe announce Immunocal's inclusion inthe 2000 Edition of the U.S.Physicians' Desk Reference .

Physicians have relied on the PDRfor up-to-date information on prescrip-tion drugs for over 50 years. It is con-sidered the standard prescription drugreference and can be found in virtuallyevery physician's office, hospital andpharmacy in the United States. You mayhave already seen it - it is the huge vol-ume your doctor consults when pre-scribing a new medication.

Immunocals inclusion is a reflectionof our credibility within the medicalcommunity. A result of our recognitionby Medicare/Medicaid.

The publisher, Medical Economics,also produces smaller, companion vol-umes featuring herbal medicines andnon-prescription drugs. These maycontain references to our competitors.Only Immunocal is included amongstthe 4000 entries in the PDR.


2/4

David Miller is a full- time scientific consultant for Immunotec.

To speak ofDavid Miller and hiswife Jeannie Gibbsas activists is a gra-cious understatement.The couple have beendevoted to helping thosesuffering from HIV and AIDSon multiple levels for manyyears. Since they themselveshave been struggling with lifewith HIV they have a uniqueawareness of the virus debil-itating effects. As trained cli-nicians and scientists theyhave an evolved knowledgeof how AIDS painfully des-troys an individuals immu-ne system. They activelyfight to help sufferers andare pursuing research to ensureindividuals receive the treatmentsthat will prolong and raise their qualityof life.

Miller was first exposed toImmunotec Research Ltd. at the NewLife Expo in New York City while hewas a volunteer for the New York StateFDA Health Board Task Force. Millerwas impressed with the simplicity ofImmunocal: a whey protein concentratethat raises glutathione levels in order tomaintain a healthy immune system. Hewas even more impressed when henoted the positive effects that hiswife experienced with the product.What he saw was extraordinary im-provement in less than two months ofuse, and a new avenue to explore forthe vast community of people affect-ed by the insidious disease. A simpleproduct, but with enormous potential.Most people with AIDS suffer frommalnutrition due to massive doses ofanti-viral drugs - if they dont eat, theirbodies cannot absorb the drugs. By

taking vitamin and mineral supplementsaggressively, they substantially increasetheir chances for a longer life.

Miller is working to increase theprofile of Immunocal within the phar-maceutical indus-try by focusingattention on itsscientific back-

ground. He isorganizing an

observatio-nal study that will be a retro-

spective analysis of 100patients on Immunocal.

Attention mustbe given to the highcosts and difficulties

in obtaining treatmentfor AIDS patients. With

many prescriptions un-affordable, the alternative therapies takeon added significance. Despite the pres-ence of buyers clubs like Direct AIDSAlternative Information Resources(DAAIR), who provide vitamins, minerals,

and neutraceuti-cals at only a 10%mark-up, manypeople are still leftwith little choiceand even lesshope.

Jeannie Gibbs is one of the foundingmembers of GAARI - Global AfricanAIDS Relief Initiative (Swahili for "life") -that provides medicines for impover-ished areas of Africa where there is noavailable treatment. It is now one of the

leading HIV donation organizations inthe world. Originally conceived at the12 th World AIDS conference, it beganby collecting drugs from patients whodonated them. Miller and Gibbs havenow seen that Immunocal is supplied toGAARI in order to help those less fortu-nate than themselves who are sufferingfrom HIV and AIDS abroad.

When asked how he continues topursue his work with such fervor up to20 hours a day, Miller simply states:"Hate. I hate this virus. Ive never seenanything worse. We have some optionsto make things better."

Together David Miller and JeannieGibbs pursue their active crusade toimprove the lives of those sufferingfrom this disease, and urge individualsand industries alike to join the fight.

2

THE ENTREPRENEUR

"The Entrepreneur" is published by:

Immun otec Research Ltd.292 Adrien PatenaudeVaudr euil-Dorion , QuebecCanada J7V 5V5

Editor: Tim ThomasEditorial Assistant: Kathryn Stephens

Chuck Roberts, PresidentJohn Andrique, V.P. Pur cha sin gGustavo Bouno us, M.D., Dir. R & DCynthia Burrier, Dir. Sales & Marketin gJacques Cohen , V.P. Oper ation sJohn H. Molson, V.P. R & DRichard Patte, Exec . V.P.Tim Thomas, V.P. Mark etin g

"The Entrep reneur " welcomes yourcontr ibutions, including trainin g ideas,business building t ips, commen ts andsuggestions. Where app ropr iate, kindlyinclude a photo.

Please send your ideas in writing to:

The Entrepreneurc/o Imm unotec Research Ltd.292 Adrien PatenaudeVaudr euil-Dorion , QuebecCanada J7V 5V5

or

e-mail to kathryn @immun ocal .com

Immunotec By the Numbers

Order Department:888-462-3397Entrepren eur Services:888-917-7779Health Care Supp ort & Ordering:877-424-5050Head Office (Main number):450-424-9992Fax Number:450-424-9993

Training Call (Mon . 10 p.m . EST):619-707-8015 (access # 5050)Opp . Call (Thu rs. 10 p .m. EST):800-991-9019 (access # 941925)Sizzle Call (24 hr s./7 d ays):888-784-2222Replay:415-273-6003Voice/Fax Bulletin Board:415-273-6004

Internet:www.immunocal .comE-mail:info@imm un ocal.com

Order repr ints of "The Entrep reneur ":

50 for $10.00100 for $20.00

500 for $100.00

Immunoca l is a registered trademark of Immun otec Research Ltd.

T he statements made throughout this issuehave not been evaluat-ed by theF DA or Health and WelfareCanada. T heproductsare not intended to diagnose, cure, prevent or t reat any disease.

Printed in Canada

ImmunocalImpact s AIDS Communit yDavid Miller & Jeannie Gibbs, Activists

The Entrepreneu r

"With many prescriptions unaffordable,

the alternative therapies take

on added significance."

Networking - that's what it's allabout! And to the best of our ability,we want to give you a chance to net-work with fellow distributors.

Send us the particulars about theBusiness Opportunity Meetings andTraining Sessions that you are planning

and we'll do our best to make peopleaware of them. We have a growing listof tools at our disposal - our web site,the Immuno-Tel system, fax flashes,check inserts and more.

Please be sure to give us sufficientlead time and don't forget the details -

date, time, place, price of admission,host, speaker. Publication will be subjectto space restrictions and availability.

We look forward to helping youpromote your events! Send your infor-mation to the attention of the Marke-ting Department - by fax to (450) 424-9993 or by email to:[email protected].

"I hate this virus. Ive never seen

anything worse. We have some options

to make things better."

T he couple's level of commitment t o their work is reflected in their activ it ies:

David Miller Has worked for 5 years in the education department at the

AIDSCenter of Queens county

Clinician at t he Mt . Sinai School of MedicineJack Martin AIDSFund Clinic Completing an MPH-PHD in Epidemiology Affi liated with ACT-UP, t he largest AIDSservice and advocacy

group in North America At tended the 12th World AIDSConference in Geneva Will attend the Internati onal Conference on Ant i-Microbiological

Agents and Chemotherapy where he will run a poster session thatwil l involve Immunocal

Jeannie Gibbs Senior editor for t he International Chronicle of Therapeutic Developments

in AIDSResearch A founding member of GAARI (Global Afri can AIDSRelief Init iative)

T hese are astounding accomplishments for anyone, let alone two people infected wi th H IV; a credit both to their choice of treatment and their unw avering determinat ion.


3/4

February 1999.The entrepre-neur with the highest number of direct-ly-sponsored new Ventures will earn atrip for two to Hawaii, including airfareand accommodations for one week.

The winner will stay at the deluxeKaanapali Alii Resort, located on thebeautiful island of Maui.

Steve Petrosino, Ohio 18Lung Chen, Texas 18Melvin Karsten, Michigan 17SoniaTsai, Ontario 17Bob Page, Florida 17Lucie Bouchard, Quebec 17

Immunotec apart from most other net-work marketing companies. In contrastto other companies in the industry, wedo not use or endorse the use of testi-monials. We choose instead to use sci-entific research and clinical studies tovalidate Immunocal. Immunotec investsheavily in independent clinical research -and the resulting credibility pays off forour entrepreneurs. This far-sighted cor-porate investment strategy is unusual in

the industry.Why has Immunotec chosen the

research route? First of all, because thedevelopment of Immunocal is a culmi-nation of over 20 years of research byDr. Gustavo Bounous, M.D. His work isstill cited by the competition. Secondly,clinical research and independent trialsare the only recognized methods tosubstantiate health claims. Finally, andmost importantly, at Immunotec we areconvinced that our research intoImmunocal's ability to raise cellular glu-tathione in humans will have far-

reaching implications in both healthmaintenance and disease prevention.

We are a different kind of networkmarketing company with a truly remar-kable product - Immunocal.

IMMUNOCAL Pioneered the research into whey

proteins Clinically proven to raise intracellular

glutathione Covered by Medicare/Medicaid 5 U.S. patents, 1 Canadian and

1 Australian Ongoing clinical research Listed in the highly respected

Physicians' Desk Reference (PDR) Listed in the pharmacists'Red Book Individually packaged dosage for

purity and freshness Not instantized for maximum

bioactivity Third party validation Abstracts on Medline and

Pubmed (Internet) Books/publications on Immunocal

3

Aloha Hawaii!Top Recruiter to Win Trip for Two

Immunocalcontinued from page 1

We now have more details on theHawaii prize package for the President'sAward winner as this year's topImmunotec recruiter.

In early January 2000, we willannounce the name of the entrepre-neur who sponsored the most newVenture entrepreneurs since thePresident's Award was instituted in

As of September 30 th , the top twelve year-to-date standings were as follows:

John Altshuler, Iowa 25Lise Lebel & Sylvain Dion, Quebec 22Peggy Iwama, British Columbia 22Sandi Walper, Alberta 20 Jeanette Gagnon, Quebec 19 Judd Anderson, British Columbia 18

Summit 2000 ResultsCongratulations to All Qualifiers

Full Package

J. AltshulerA. AndersonDr. J. Anderson J. AndersonAnomaly ProfilesS. AzevedoD. BinnieL. Bouchard J. BradnerB. CarellaH. ChanW. CheungV. Cupler

M. MotykaC.OBrienG. OuelletA. OwusuV. Pitti

K. RandallW. Rapp J. RaughtonA. RecintoRoberts Future J. Scheetz

M. GrayM. HackettE. HaysA. ImbaultM. Karsten

C. Lavoie J. LevisD. McNabM. McPhersonR. MillerD. Montgomery

S. ShafferS. SilversS. SkollarM. St-CyrC. Swartzentruber

P. TsuC. VeilleuxR. WeldonB. WhiteL. Yu

Immunotec would like to congratu-late and acknowledge all qualifiers forthe Summit 2000 event in October at

Kaanapali Alii Resort, Maui, Hawaii.

Congratulations!President's Award Winners Go to Tremblant

Sandi Walper

June Winner

John Tsai

July Winner

Douglas Binnie

August Winner

Referencecontinued from page 1

During the months of June, July andAugust, winners of the President'sAward automatically earned all-inclusivepackages to Mont Tremblant for the

Summit 2000 Meeting on the Mountain- and special recognition at our FallEvent.

The Eagle Trophy is awardedmonthly to the entrepreneur whorecruited the most front-line Ventures inthe network. The end-of-the year win-

ner earns a deluxe vacation in Hawaii.(See Aloha Hawaii article)

M. LebelS. Lowy

D. Luboff J. Marcoux J. McCallumH. MeghdadiF. Melanon J. Mollohan J. MoncriefR. MotykaB. MulgrumS. Petrosino

L. CurrieM. Dagenais

E. DionV. Dominguez J. GagnonT. GuengerichA. HansenF. HarpainL. Hawker J. HawleyP .IwamaC. KralikL. Lebel & S. Dion

R. PlamondonC. Rosang

P. SchafferS. Schaffer J. SpencerTeam ImmunotecTop Gun J. TsaiM. TsaiT. Tsis J. ViauS. Walper

Mont Tremblant, Canada. A total of 95distributors qualified either for a fullevent package or a land package.

No longer will entrepreneurs needto give lengthy explanations to mem-bers of the healthcare community. Asimple reference to the PDR will put thedocumentation at their doctor's finger-tips.

The Physicians' Desk Reference -another tool that proves Immunocal'suniqueness. Immunotec Research - ouremphasis on credibility reaps rewards.

We're in the Red Book too! ThePharmacist's primary reference, the Red Book, has been in use for more than acentury. Used as a source for accurateproduct information and prices on pre-scription drugs and over-the-counterproducts as well as accessories and sup-plies, the Red Book is published annually.It contains hard-to-find reference informa-tion to assist in third-party and govern-ment reimbursement and answers theclinical questions common in the industry.Rated the most useful non-journal book inthe pharmacy. And Immunocal is there!

Be sure to check our website for the most recent standings or, if you're on theImmuno-Tel system, youll receive an update automatically.

Land Package

F. ArbarpourM. BlinickA. BorsenkoC. BrayV. Brown

J. BrundageC. BurkeF. ChowK. EyrichE. FortinC. Gagnon


4/4

Immunotec now has a brand-newway to help you mix your Immunocal.The new battery-powered blender is anupgraded version of a previous modelthat some of you may have seen.

Immunocal is a great product - butit has always been a challenge to mixthe powder in liquids. This is because

Immunocal cannot be mixed "aggres-sively," or heated, without losing theproduct's bioactivity.

Although some consumers mixImmunocal in yogurt or applesauce, etc.without any problem, the majority pre-fer to mix it in their favorite liquid, usual-ly fruit juice. Until now, Immunotec rec-ommended using the Immunotec shak-er or making a paste out of the powderbefore adding the remaining liquid.

Now the new, improved Immu-notec blender takes the hassle out ofmixing Immunocal. Simply pour the liq-uid in the blender, add Immunocal,close the cover, press and hold the mixbutton for approximately 30 seconds.Presto! The powder is completely dis-solved into a smooth, creamy consis-tency. No lumps! You can even drinkright out of the blender.

Clean-up is a breeze. Simply detachthe container from the base and washwith soap and water. The base shouldnot be immersed in water. Be sure tocontact Customer Service for moredetails.

4

NewIm munocal MixerImproved Blender Makes Mixing Foolproof

The new and improved Immunocal blender.

Susan Lee FornoAZ

Steven Petrosi noOH

B L U E C H I P(photo unavailable)Cupler Virginia - MDNoland Janis - FLPage Bob - FLPotentials Development - NYRapp William & Jane - NYSuttles James H. - MDBorsenko Alec - ONChan Ho Yen - ONFarbiasz Miriam - ONHarpain Franz - BCIp Catherine - ONIwama Peggy - BC

Lariviere Nicole - QCLukinuk Brendt - ABMotyka Mary - QCReodica Armando - ONRosang Cliff - BCZobel Alicja M - ON

FORTUNEAliberto John Vincent - NJAzevedo John T. - CABentley David - CTCales Nancy - ILChay Whileon - NYClaire Barbara - KYClayton Melinda - NYCorbo Timothy R. - CADoran Michael - IA

Eagle Crest Resources - VAFerenci Mary - NYHerman Sarah J. - SDHume David L. - TXJudith A. Koski - IAKaiser Olga - CALucas Andrew E - CANebbeling David P - MINiederhauser Mary Lynn - IANoland Janis - FLSchaffer Sharon L. - FLScheetz John - IA

Silver Steven - FLThompson Wendie - WIWeldon Robert I. - FLWendt Lynn M. - MIWhite Lyn - COWu Tien-Lung - CAYoung Carol - IDBataga Rizalino - ONBerthiaume Christine - QCBray Colette - ONBrundage John & Jennifer - ONChan Pui Yen - ONChan Elizabeth - ONChang Kitty - ONCheng Chu Li - BCDagenais Marion - QCDave Star Enterprises - ON

Dion Estelle - QCFord John R. - ONFortin Ernest - QCGagnon Germain - QCGenest Lucie Bouchard - QCGray Monica R. - ONHarpain Franz - BCIwama Peggy J. - BCLamarche Evangeline - QCLanthier Gilles - QCLavoie Claudine - QCLe Cren Frederic - QC

McPherson Mary - ONMills Marie - ONMontgomery Don J. - ONPinder Catherine - ONRandal Keith - ONReodica Andy - ONReodica Armando - ONRideout Jeanne Mary - ONRosang Cliff - BCSaint-Germain Pierre - QCSamuels Pauline E. - ONThompson Camelia - QCTin Suk - ONVeilleux Claire- QCWolny Janusz - QCZobel Alicja - ON

William RappNY

Anita RuizCA

Lucie BouchardQC

Wendy CheungON

Roger PatolaON

John Y. TsaiON

Doug & Mae DrysdaleON

Lise Lebel & Sylvain DionQC

Martha TsaiON

Anita WeissON

Market LeadersBlue Chip

interest shown in Immunocal followingthat one-hour special.

Q: Earlier you mentioned your researchwith Chronic Fatigue Syndrome. Arethere similarities with your research onImmunocal and prostate cancer, or is ita distinctly separate project?

A: The studies are quite different inboth design and detail. I am in theprocess of organizing a multi-centrictrial on Chronic Fatigue Syndrome withImmunocal as a treating agent. The twostudies cannot really be directly com-pared since Chronic Fatigue Syndromeis a more difficult disease to diagnoseand evaluate. There are many biochem-ical parameters that need to be moni-tored during the clinical trial, and morelaboratory work is needed to assess a

patients response to treatment.Q: What hope can we offer to thoseawaiting the results of researchers suchas yourself?

A: I believe that we will soon be able tooffer more than just hope. Prostate can-cer is the number one cancer killeramong men, and as I stated earlier, pre-liminary results reflect a prelude to big-ger and better things. Chronic FatigueSyndrome demands more in-depthexamination due to the nature of thedisease. Because of the limited research

lower levels of Prostatic SpecificAntigen (PSA) in the benign cases.One of those cases concerns a cancerpatient who had a remarkable experi-ence where the disease was complete-ly widespread last summer and the PSAlevel was about 200, which is far toohigh. One year later, after using Immu-nocal, the level is way down and thepatient shows no evidence of cancerspread. It is clear that Immunocal playeda substantial role. Needless to say, I amnot shy in stating my belief in the bene-ficial effects of Immunocal.

Q: How did you first hear aboutImmunocal and Immunotec Research?

A: During exchanges of information onthe Internet involving Chronic FatigueSyndrome, the company and product

were spoken of favorably. There is aninterest in Immunocal and in the theoryof how raising the level of intracellularglutathione is beneficial for an individ-uals health. Soon after hearing of theproduct, I had Dr. Gustavo Bounous andMr. John Molson of Immunotec on myradio show on WEVD in New York todiscuss it in more detail. The show is aterrific forum for discussion of signifi-cant studies that examine the causesand treatment for conditions that peo-ple want to know more about. We nowhave a world-wide audience and I cantell you that there was substantial

currently available, there is hope just inthe fact that attention is being paid tothe problem. I see Immunocal as a po-tentially valuable treatment modalityand I think it is important to note that Iprescribe it to patients other than thosementioned in these specific studies.

Q: With all your years dedicated toresearch and helping people, what lega-cy would you like to leave?

A:I would like to make a contribution tothe clinical aspect of medicine while re-lieving peoples suffering and consider

this to be a rewarding experience. Myextensive work with Chronic FatigueSyndrome and prostate cancer willhopefully supply some important find-ings which would be very exciting andthrilling for me. I feel that Im doingsomething substantial in these areas.

Dr. Mazlencontinued from page 1